Treats hypertension. ANDA 213349, held by Chartwell RX. Nebivolol Hydrochloride.
As of Nov 21, 2026, ANDA 213349 (Nebivolol Hydrochloride), held by Chartwell RX, was first approved by FDA on Mar 31, 2022, with 1 approved supplement and 0 published complete response letters.
Nebivolol tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2022 | Original application | Approved | None posted |
| Nebivolol HydrochlorideEQ 2.5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 5MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 10MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Nebivolol HydrochlorideEQ 20MG BASE · tablet;oral | Nebivolol Hydrochloride | Discontinued |
| Aug 25, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 31, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters